SCHEMBL480137

SCHEMBL480137

Cn1cc(C(=O)O)ccc1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 1/20 0.58
TP53 P04637 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 5/20 0.46
HTT P42858 3/20 0.46
MEN1 O00255 3/20 0.46
ALDH1A1 P00352 7/20 0.43
HPGD P15428 4/20 0.43
MAPT P10636 3/20 0.43
LMNA P02545 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
SRD5A2 P31213 2/20 0.41
BRD4 O60885 1/20 0.40
KDM4E B2RXH2 4/20 0.40
TDP1 Q9NUW8 3/20 0.40
POLB P06746 1/20 0.39
APEX1 P27695 1/20 0.39
DDAH1 O94760 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3673691 0.89 CREBBP (0.50) CREBBPTP53TSHRKMT2AHTT
SCHEMBL2945858 0.84 CREBBP (0.49) CREBBPTP53TSHRALDH1A1SMN1; SMN2
SCHEMBL4585032 0.83 CREBBP (0.46) CREBBPKMT2AHTTMEN1ALDH1A1
SCHEMBL19159666 0.81 CREBBP (0.45) CREBBPKMT2AHTTMEN1ALDH1A1
SCHEMBL21384072 0.81 CREBBP (0.45) CREBBPKMT2AHTTMEN1ALDH1A1
SCHEMBL709323 0.81 BRD4 (0.47) CREBBPKMT2AHTTMEN1ALDH1A1
SCHEMBL28300808 0.81 BRD4 (0.47) CREBBPKMT2AHTTMEN1ALDH1A1
SCHEMBL13890744 0.79 KDM4E (0.46) CREBBPKMT2AHTTMEN1ALDH1A1
SCHEMBL13702366 0.78 BRD4 (0.54) CREBBPTSHRKMT2AHTTMEN1
SCHEMBL2034671 0.78 LMNA (0.51) CREBBPTSHRKMT2AHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 330 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024112806-A1 GENERATION AND USE OF EPIGENETIC MAPS FOR DRUG DISCOVERY MOONWALK BIOSCIENCES, INC. (US) 2024-05-30 WO claimed
EP-3174852-B1 ARYLHYDRAZIDES CONTAINING A 2-PYRIDONE MOIETY AS SELECTIVE ANTIBACTERIAL AGENTS ABAC THERAPEUTICS S L (ES) 2018-07-18 EP claimed
US-9840467-B2 Arylhydrazides containing a 2-pyridone moiety as selective antibacterial agents ABAC Therapeutics, S.L. (ES) 2017-12-12 US claimed
US-20170217887-A1 ARYLHYDRAZIDES CONTAINING A 2-PYRIDONE MOIETY AS SELECTIVE ANTIBACTERIAL AGENTS ABAC Therapeutics, S.L. (ES) 2017-08-03 US claimed
EP-3174852-A1 ARYLHYDRAZIDES CONTAINING A 2-PYRIDONE MOIETY AS SELECTIVE ANTIBACTERIAL AGENTS ABAC THERAPEUTICS, S.L. (ES) 2017-06-07 EP claimed
WO-2016016291-A1 ARYLHYDRAZIDES CONTAINING A 2-PYRIDONE MOIETY AS SELECTIVE ANTIBACTERIAL AGENTS FERRER INTERNACIONAL, S.A. (ES) 2016-02-04 WO claimed
US-8524774-B1 Topical two step polytherapy for treatment of psoriasis and other skin disorders CYMBIOTICS, INC. (US) 2013-09-03 US claimed
US-20100048579-A1 PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS ARISTA LUCA 2010-02-25 US claimed
EP-2146970-A1 PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISIS Novartis Ag (CH) 2010-01-27 EP claimed
WO-2008125627-A1 PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISIS NOVARTIS AG (CH) 2008-10-23 WO claimed
US-4258052-A APPLYING TOPICALLY YU RUEY J 1981-03-24 US claimed
EP-4737449-A1 P53-Y220C SELECTIVE SMALL-MOLECULAR REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Changchun Genescience Pharmaceutical Co., Ltd. (CN) 2026-05-06 EP disclosed
EP-4727599-A2 POLY(OXAZOLINE) CONJUGATES WITH PENDANT CATIONIC GROUPS AND LIPID NANOPARTICLES AND POLYPLEXES INCLUDING SAME Serina Therapeutics (AL), Inc. (US) 2026-04-22 EP disclosed
EP-4727939-A1 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2026-04-22 EP disclosed
EP-4713306-A1 NOVEL TRACER FOR THE IN VIVO DETECTION OF THE AGGREGATION OF ALPHA-SYNUCLEIN Stichting Amsterdam UMC (NL) 2026-03-25 EP disclosed
WO-2004031175-A2 N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-04-15 WO disclosed
US-20030216758-A1 Coated surgical patches ANGIOTECH PHARMACEUTICALS, INC. (CA) 2003-11-20 US disclosed
US-20030144570-A1 Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors ANGIOTECH PHARMACEUTICALS, INC. (CA) 2003-07-31 US disclosed
US-20020055666-A1 Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors ANGIOTECH INTERNATIONAL AG (CH) 2002-05-09 US disclosed
US-4258052-A APPLYING TOPICALLY YU RUEY J 1981-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217887-A1 ARYLHYDRAZIDES CONTAINING A 2-PYRIDONE MOIETY AS SELECTIVE ANTIBACTERIAL AGENTS ABCC5, AAAS, PDXK CREBBP 747/4885TP53 4762/4885TSHR 3550/4885
US-20100048579-A1 PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS GPBAR1, GPER1, ADRB1 CREBBP 2067/4885TP53 3360/4885TSHR 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.